|Podcasts|January 24, 2023

IndoUSrare: Purposeful Clinical Research For Rare Diseases In India

Author(s)Lisa Henderson, Andy Studna, Senior Editor

Dr. Harsha Rajasimha, Founder and Chairman of IndoUSrare, discusses the emotional reason behind founding the non-profit, programs they offer that are helping rare disease parents/patients, rare disease research in India, and much more.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing

ByAndy Studna, Senior Editor

August 25th 2026

ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

ByAndy Studna, Senior Editor

August 20th 2026

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

ByAndy Studna, Senior Editor

August 19th 2026

ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership

ByAndy Studna, Senior Editor

August 18th 2026

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

ByAndy Studna, Senior Editor

August 17th 2026

IndoUSrare: Purposeful Clinical Research For Rare Diseases In India

Related Content

ACT Brief: Payment Performance as Operational Brand, Speed and Discipline in Biotech Development Strategy, and Non-GLP-1 Obesity Candidate Licensing

ACT Brief: AI Architecture and Model Ownership Due Diligence, FDA Framework for Generative AI Medical Devices, and Heidi Overton Nominated for FDA Commissioner

ACT Brief: Phase I Back-Office Automation Priorities, Early Phase Data Interpretation Under Capital Pressure, and Syneos AI Ecosystem Expansion

ACT Brief: TrialBlazer Timeline Reductions and Operational Demands, Structural Trial Collaboration and Site Integration, and Henlius-Sandoz Biosimilars Partnership

ACT Brief: Data Standardization Bottleneck in Real-Time Monitoring, US Biotech FIH Trial Regulatory Frustration, and FDA Approval of Zenbexus for Multiple Myeloma

Trending on Applied Clinical Trials Online

When the Slack Runs Out: AI and the CRO Operating Model

Why Payment Performance Has Become a Competitive Differentiator for Sponsors

ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery

Why Site Payment Inconsistency Has Persisted for So Long

Speed, Discipline, and the New Rules of Biotech Development: Q&A with Stella K. Vnook, PhD, Kaida BioPharma and Aviva Ventures